In 2024, Zhao et al. [33] observed that anti-IL-17 therapy (secukinumab) was associated with a trend toward normalization of the gut microbiome in 14 psoriasis patients, underscoring the complex interplay between this cytokine and the microbiota. This evidence concerns the gene IL17A and psoriasis.